PDCD1 and cancer: Cancer immunotherapy has made great progress due to immune checkpoint inhibitors targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) in the clinic (1–3).